Compare AbCellera Biologics Inc (ABCL) vs Ares Capital Corporation (ARCC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Ares Capital Corporation — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Ares Capital Corporation trades at $18.35 (market cap $13.26B). The key difference: Ares Capital Corporation is far larger — about 5.6× AbCellera Biologics Inc's market cap, and Ares Capital Corporation pays a 10.4% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ARCC | |
|---|---|---|
Market Cap | $2.35B | $13.26B |
Sector | Health | Financials |
52-Week High | $8.12 | $23.25 |
52-Week Low | $2.78 | $17.45 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 10.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ARCC trades at $18.47, down 1.39% on the day, near its consensus low price target of $18.50. The stock shows neutral technical signals with mixed moving averages and oscillators. Recent quarterly EPS results have missed expectations, though the company maintains a high net income margin of 84.5%. A dividend of $0.48 is scheduled for payment on June 30, 2026, supporting income-focused strategies.
Outlook remains cautiously optimistic given strong analyst support (24 Buy, 8 Hold) and a $20.58 consensus target implying ~11% upside. Risks include earnings misses and revenue declines from $1.7B in 2024 to a projected $1.4B in 2026. The stock's P/E of 11.39 and P/B of 0.95 suggest reasonable valuation amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →
